Two case reports of patients with metastatic melanoma treated with Denosumab and ipilimumab (anti-CTLA4 therapy) induced potent and near complete clinical responses above what was expected for ipilimumab alone, suggesting that RANKL inhibition can enhance the anti-tumor effects of checkpoint inhibition (162, 163). The gene discussed is TNFSF11; the disease is neoplasm.